Ning Li, MD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Emerging Leaders
not ranked
Current Leaders
#2352 pts
All-Time Leaders
#5,57910 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2012. 19 trials as lead/chair. How it works →
Trials led — by scientific impact
A Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics (PK/PD) and Preliminary Efficacy of ABO2011 Monotherapy or in Combination With Toripalimab in Patients With Advanced Solid Tumors
Phase 2RecruitingSuzhou Abogen Biosciences Co., Ltd.
2
impact
A Phase Ib, Open Label, Multicenter Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
Phase 1RecruitingJemincare
2
impact
An Open-label, Single-arm Phase 2 Study of ES014 in Subjects With Advanced Solid Tumors
Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences
2
impact
An Open, Single-arm, Phase II Clinical Study to Evaluate the Efficacy and Safety of LTC004 in Combination With Toripalimab in Patients With Advanced Solid Tumors Resistant to First-line Immunotherapy
Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences
1
impact
A Phase I/II Clinical Study of TC-N201 Injection for the Treatment of Advanced Solid Tumors With HLA-A2 Expression and Positive NY-ESO-1.
Phase 1RecruitingTCRCure Biopharma Ltd.
1
impact
A Phase I Study of Evaluating the Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors
Early Ph 1RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences
1
impact
Single Arm, Phase I Clinical Study of HS-IT101 Injection in the Treatment of Advanced Solid Tumors
Phase 1RecruitingQingdao Sino-Cell Biomedicine Co., Ltd.
0
impact
An Open-label, Single-arm, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Efficacy of MTM-H-001 in the Treatment of Adult Participants With Relapsed or Refractory B-cell Malignancies (Archonc-001)
N/ANot Yet RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences
0
impact
A Phase I Platform Study of Target-Based Screened CAR-Macrophages for the Treatment of Advanced Malignant Tumors
Early Ph 1Not Yet RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences
0
impact
An Early, First-in-Human, Investigator-Initiated, Open-label Study to Assess the Safety, Feasibility, Cytokinetics, and Preliminary Antitumor Activity of GC511B in Adult Trial Participants With DLL3+ Relapsed/Refractory Small Cell Lung Cancer
Phase 1RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences
0
impact
A Prospective, Randomized, Controlled Phase II Clinical Study of Albumin-Bound Paclitaxel/Carboplatin Combined With Aitua Combination Antibody (PD-1/CTLA-4 Bispecific Antibody) for the Neoadjuvant Treatment of Advanced High-Grade Serous Ovarian Cancer With Unsatisfactory Debulking
Phase 2Not Yet RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences
0
impact
A Single-Arm, Open-Label Phase I/II Clinical Trial of Intraperitoneal Perfusion of SK-NK Cell Injection for the Treatment of Advanced Ovarian Cancer Patients With Massive Ascites
Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences
0
impact
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Dose Expansion Study of FTL008.16, a Recombinant Anti-CD137 and Anti-5T4 Bispecific Antibody, in Patients With Advanced or Metastatic Solid Tumors
Phase 1RecruitingSound Biopharmaceuticals Ltd.
0
impact
A Single-arm, Open-label, Single/Multiple-dose Escalation, and Cohort Expansion Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Oral CSCJC3456 Tablets in Patients With Advanced Malignant Solid Tumors
Phase 1RecruitingChangshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
0
impact
A Single-arm, Dose-escalating Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetic , and Efficacy of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors
Phase 1Not Yet RecruitingSuzhou Maximum Bio-tech Co., Ltd.
0
impact
An Open-label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of CREPT-618 in Patients With Locally Advanced Hepatocellular Carcinoma
Phase 1RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences
0
impact
A Clinical Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Immunogenicity of the Novel RNA Tumor Vaccine Targeting MICA/B Stress Proteins in Patients With Advanced Solid Tumors
Early Ph 1ActiveNING LI
0
impact
Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastases of B7H3+ Solid Tumors
N/ACompletedCancer Institute and Hospital, Chinese Academy of Medical Sciences
0
impact
A Umbrella Study to Evaluate the Safety and Preliminary Efficacy of Combined or Sequential Immunotherapy in Patients with Advanced Solid Tumors Progressing on Clinical Trial Drugs
Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences
0
impact
A Phase I Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBR854 Cell Injection in Patients With Unresectable Locally Advanced Or Metastatic Solid Tumors
Phase 1UnknownImbioray (Hangzhou) Biomedicine Co., Ltd.
0
impact
0
impact
A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CG001419 Tablets in Adult Patients With Locally Advanced/Metastatic Solid Tumors Harboring NTRK Gene Fusions, Mutations, or Amplification/Over Expression.
Phase 2RecruitingCullgen (Shanghai),Inc
0
impact
Comparative Study of Neoadjuvant Chemo/Brachytherapy and Chemotherapy Alone Before Radical Hysterectomy in Stage Ib2-IIa2 Cervical Cancer
N/ACompletedChinese Academy of Medical Sciences
0
impact